WO2004056353A3 - Device and method for delivering mmp inhibitors - Google Patents

Device and method for delivering mmp inhibitors Download PDF

Info

Publication number
WO2004056353A3
WO2004056353A3 PCT/EP2003/014602 EP0314602W WO2004056353A3 WO 2004056353 A3 WO2004056353 A3 WO 2004056353A3 EP 0314602 W EP0314602 W EP 0314602W WO 2004056353 A3 WO2004056353 A3 WO 2004056353A3
Authority
WO
WIPO (PCT)
Prior art keywords
delivering
mmp inhibitors
local administration
optionally
formula
Prior art date
Application number
PCT/EP2003/014602
Other languages
French (fr)
Other versions
WO2004056353A2 (en
Inventor
David Saul Cohen
Margaret Forney Prescott
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
David Saul Cohen
Margaret Forney Prescott
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0229896A external-priority patent/GB0229896D0/en
Priority claimed from GB0229891A external-priority patent/GB0229891D0/en
Priority claimed from GB0229895A external-priority patent/GB0229895D0/en
Application filed by Novartis Ag, Novartis Pharma Gmbh, David Saul Cohen, Margaret Forney Prescott filed Critical Novartis Ag
Priority to AU2003294917A priority Critical patent/AU2003294917A1/en
Publication of WO2004056353A2 publication Critical patent/WO2004056353A2/en
Publication of WO2004056353A3 publication Critical patent/WO2004056353A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/434—Inhibitors, antagonists of enzymes

Abstract

The invention relates to the local administration of a matrix metalloproteinase inhibitor of formula (I), or a pharmaceutically acceptable salt thereof, optionally in conjunction with one or more other active ingredients, and a device adapted for such local administration.
PCT/EP2003/014602 2002-12-20 2003-12-19 Device and method for delivering mmp inhibitors WO2004056353A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003294917A AU2003294917A1 (en) 2002-12-20 2003-12-19 Device and method for delivering mmp inhibitors

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0229891.7 2002-12-20
GB0229896.6 2002-12-20
GB0229895.8 2002-12-20
GB0229896A GB0229896D0 (en) 2002-12-20 2002-12-20 Organic compounds
GB0229891A GB0229891D0 (en) 2002-12-20 2002-12-20 Organic compounds
GB0229895A GB0229895D0 (en) 2002-12-20 2002-12-20 Organic compounds

Publications (2)

Publication Number Publication Date
WO2004056353A2 WO2004056353A2 (en) 2004-07-08
WO2004056353A3 true WO2004056353A3 (en) 2004-11-04

Family

ID=32685758

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/014602 WO2004056353A2 (en) 2002-12-20 2003-12-19 Device and method for delivering mmp inhibitors

Country Status (2)

Country Link
AU (1) AU2003294917A1 (en)
WO (1) WO2004056353A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403775B2 (en) 2003-04-24 2016-08-02 Incyte Corporation AZA spiro alkane derivatives as inhibitors of metalloproteases

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120046724A1 (en) * 2006-07-13 2012-02-23 Anna Norlin Weissenrieder implantable cardiac stimulation drug releasing electrode

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000214A1 (en) * 1994-06-24 1996-01-04 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors
WO1997022587A1 (en) * 1995-12-15 1997-06-26 Novartis Ag Alpha-substituted arylsulphonamido hydroxamic acids as tnf-alpha and matrix metalloproteinase inhibitors
WO1998007697A1 (en) * 1996-08-23 1998-02-26 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
WO1998014424A1 (en) * 1996-10-02 1998-04-09 Novartis Ag Hydroxamic acid derivatives
WO1998042662A1 (en) * 1997-03-20 1998-10-01 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
WO2000056283A1 (en) * 1999-03-24 2000-09-28 The B.F.Goodrich Company Inhibition of matrix metalloproteinases with polymers and pharmaceutical applications thereof
US6194451B1 (en) * 1997-01-31 2001-02-27 Pharmacia & Upjohn S.P.A. Matrix metalloproteinase inhibitors
EP1088550A1 (en) * 1999-10-01 2001-04-04 Pfizer Products Inc. alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders
WO2002055121A1 (en) * 2001-01-11 2002-07-18 Biocompatibles Uk Limited Drug delivery from stents

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000214A1 (en) * 1994-06-24 1996-01-04 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors
WO1997022587A1 (en) * 1995-12-15 1997-06-26 Novartis Ag Alpha-substituted arylsulphonamido hydroxamic acids as tnf-alpha and matrix metalloproteinase inhibitors
WO1998007697A1 (en) * 1996-08-23 1998-02-26 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
WO1998014424A1 (en) * 1996-10-02 1998-04-09 Novartis Ag Hydroxamic acid derivatives
US6194451B1 (en) * 1997-01-31 2001-02-27 Pharmacia & Upjohn S.P.A. Matrix metalloproteinase inhibitors
WO1998042662A1 (en) * 1997-03-20 1998-10-01 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
WO2000056283A1 (en) * 1999-03-24 2000-09-28 The B.F.Goodrich Company Inhibition of matrix metalloproteinases with polymers and pharmaceutical applications thereof
EP1088550A1 (en) * 1999-10-01 2001-04-04 Pfizer Products Inc. alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders
WO2002055121A1 (en) * 2001-01-11 2002-07-18 Biocompatibles Uk Limited Drug delivery from stents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FINK C A ET AL: "Design and synthesis of thiol containing inhibitors of matrix metalloproteinases", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 9, no. 2, 18 January 1999 (1999-01-18), pages 195 - 200, XP004152599, ISSN: 0960-894X *
GOBELL F ET AL: "BIODIVYSIO STENT COATED WITH METALLOPROTEINASE INHIBITOR REDUCES NEOIN", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 104, no. 17, SUPPL II, 23 October 2001 (2001-10-23), pages II - 388, XP009028065, ISSN: 0009-7322 *
KOTTIRSCH GEORG ET AL: "beta-Aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme", JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 11, 23 May 2002 (2002-05-23), pages 2289 - 2293, XP002290121, ISSN: 0022-2623 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403775B2 (en) 2003-04-24 2016-08-02 Incyte Corporation AZA spiro alkane derivatives as inhibitors of metalloproteases

Also Published As

Publication number Publication date
WO2004056353A2 (en) 2004-07-08
AU2003294917A1 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
WO2002089791A3 (en) Acne treatment with lipooxigenase inhibitors
WO2005044199A3 (en) Combination of proton pump inhibitor and sleep aid
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
WO2005076987A3 (en) Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
WO2005117870A3 (en) Combination of proton pump inhibitor, buffering agent, and prokinetic agent
DK0841904T3 (en) Oral pharmaceutical preparations with delayed release of reversible proton pump inhibitors
EA200400966A1 (en) NEW MEDICATED FORMS OF SUBSTITUTED BENZIMIDAZOL AND METHOD OF THEIR APPLICATION
WO2003065988A3 (en) A combination for treating cold and cough
CY1108725T1 (en) Combination of NMDA antagonist and acetylcholinesterase inhibitors for the treatment of ALZHEIMER
CA2396159A1 (en) Novel substituted benzimidazole dosage forms and method of using same
AU2003240949A1 (en) Active agent delivery systems and methods for protecting and administering active agents
PT1727551E (en) Pharmaceutical composition comprising a benzodiazepine derivative and a inhibitor of the rsv fusion protein
WO2005011586A3 (en) Treatment and preventi0n of cardiovascular events
HK1098372A1 (en) Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein
NO20054607L (en) Nitrogen-containing heterocyclic derivative having 2,6-disubstituted styryl
WO2002008217A3 (en) COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
WO2007022509A3 (en) Use of seh inhibitors as analgesics
WO2001052897A3 (en) Therapeutic anti-inflammatory and analgesic composition containing selective cox-2 inhibitors
EP1695712A3 (en) Oral formulations for the selective inhibition of thrombin comprising boronic acid species
WO2004009583A3 (en) Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
TW200733963A (en) Cough inhibitor
SE0300445D0 (en) New combination
AU2001255393A1 (en) Halogentated 2-amino-3, 4 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
ZA200502909B (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NI NO NZ OM PG PH PL PT RO RU SC SE SG SK SY TJ TM TN TR TT UA US UZ VC VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP